Safety concerns led to the removal of droperidol from the market, resulting in many clinicians lacking experience with its use in residency or formal practice. The concerns were later found to be overstated, and there is now a resurgence of droperidol use in modern practice. Join us as we evaluate the literature and apply the evidence to make recommendations for treating patients with acute agitation.

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Describe the clinical approach to the acutely agitated patient
2. Summarize pharmacotherapy options utilized for acute agitation
3. Assess the historical data contributing to the black box warning of droperidol
4. Describe the design and results of a study evaluating the safety and efficacy of droperidol for acute agitation
5. Apply evidence in making recommendations for patient care

Ryan Cook, PharmD, BCPS, BCCCP
EM Clinical Pharmacist
Baptist Medical Center

Ryan Cook does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Calver L, Page CB, Downes MA, et al. The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioral Disturbance in the Emergency Department. Ann Emerg Med. 2015 Sep;66(3):230-238.e1. doi: 10.1016/j.annemergmed.2015.03.016. Epub 2015 Apr 15. PMID: 25890395.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: October 13, 2021
Planned Expiration Date: October 13, 2024